XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)
 3 Months Ended
Mar. 31, 2023
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Divestitures
The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
Three Months Ended March 31,
Net ProceedsDivestiture (Gains)/LossesRoyalty Income
Dollars in millions202320222023202220232022
Diabetes business (a)
$216 $172 $— $— $(188)$(170)
Mature products and other4 225 — (211)— (1)
Total$220 $397 $— $(211)$(188)$(171)
(a)    Net proceeds for diabetes business relates to net proceeds from royalties received subsequent to the sale of the diabetes business.
Licensing and Other Arrangements
The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.

Three Months Ended March 31,
Dollars in millions20232022
Keytruda* royalties
$(279)$(221)
Tecentriq* royalties
(30)(25)
Contingent milestone income(31)(41)
Amortization of deferred income(12)(12)
Other royalties and licensing income (11)(7)
Total$(363)$(306)